Maynard Um
-
-
-
-
-
-
-
AstraZeneca to present gefurulimab trial data at neurology meetings
-
-
-
-
-
-
-
Buy the pullback in this large pharma stock: UBS
-
-
-
-
-
-
-
Imfinzi plus tarlatamab shows survival gains in lung cancer trial
-
-
-
-
-
-
-
AstraZeneca's Tezspire meets endpoints in esophagitis trial
-
-
-
-
-
-
-
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
-
-
-
-
-
-
-
AstraZeneca (AZN) Tops Q2 EPS by 14c
-
-
-
-
-
-
-
AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
-
459,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

